Outcomes of treatment of severe COVID-19 pneumonia with tocilizumab: a report of two cases from Tunisia

The SARS CoV-2 pandemic is a global health threat with high morbidity and mortality (1 to 4%) rates. COVID-19 is correlated with important immune disorders, including a “cytokine storm”. A new therapeutic approach using the immunomodulatory drug, Anti-IL6 (tocilizimub), has been proposed to regulate...

Descripción completa

Detalles Bibliográficos
Autores principales: Azaiz, Mouna Ben, Chatbri, Bassem, Sellami, Walid, Romdhani, Chihebeddine, Lamine, Khaled, Ghazouani, Ezzedine, Oueslati, Ridha, Gharsallah, Hedi, Ferjani, Mustapha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641632/
https://www.ncbi.nlm.nih.gov/pubmed/34909094
http://dx.doi.org/10.11604/pamj.2021.40.126.28020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641632/
https://www.ncbi.nlm.nih.gov/pubmed/34909094
http://dx.doi.org/10.11604/pamj.2021.40.126.28020

Ejemplares similares